Using the Skindex-16 and CTCAE to assess rash symptoms: Results of a pooled-analysis (N0993). Atherton, P. , Burger, K. , Loprinzi, C. , Miller, R. , Jatoi, A. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Symptom Inter - NCCTG-N0993
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993) Atherton, Pamela J. , Burger, Kelli N. , Loprinzi, Charles L. ... - - Support Care Cancer - 2012 Manuscript - Primary - Primary - Symptom Inter - N0993
Assessment of Patient-Reported Measures of Bowel Function Before and After Pelvic Radiotherapy: An Ancillary Study of the North Central Cancer Treatment Group Study N00CA Atherton, Pamela J. , Halyard, Michele Y. , Sloan, Jeff A. ... - - Support Care Cancer - 2013 Manuscript - Secondary - Primary - Symptom Inter - N00CA
The Complementary Nature of Patient-Reported Outcomes (PROs) and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591) Atherton, Pamela J. , Watkins-Bruner, Deborah W. , Gotay, Carolyn ... - - J Pain Symptom Manage - 2015 Manuscript - Primary - Primary - Health Outcome - N0591
Patient Reported Outcomes Questionnaire Compliance in Cancer Cooperative Group Trials (Alliance N0992) Atherton, Pamela J , Burger, Kelli N , Pederson, Levi D ... - - Clin Trials - 2016 Manuscript - Primary - Primary - Health Outcome - N0992
The use of Valeriana officinalis (Valerian) in improving sleep in patients who are undergoing treatment for cancer: a phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5) Barton, D. L. , Atherton, P. J. , Bauer, B. A. , Moore, D. F. Jr ... - - J Support Oncol - 2011 Manuscript - Primary - Primary - Symptom Inter - N01C5
Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9 Barton, D. L. , Lavasseur, B. I. , Sloan, J. A. , Stawis, A. N. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary - Primary - Symptom Inter - N05C9
A phase III trial evaluating three doses of citalopram for hot flashes: NCCTG trial N05C9 Barton, D. L. , Lavasseur, B. , Sloan, J. A. , Stella, P. J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary - Primary - Symptom Inter - N05C9
Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance) Barton, Debra L. , Shuster, Lynne T. , Dockter, Travis ... - - Support Care Cancer - 2018 Manuscript - Secondary - Primary - Symptom Inter - N10C1
Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance) Barton, Debra L. , Sloan, Jeff A. , Shuster, Lynne T. , Gill, Paula ... - - Support Care Cancer - 2018 Manuscript - Primary - Primary - Symptom Inter - N10C1
Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA Barton, Debra L. , Soori, Gamini S. , Bauer, Brent A. ... - - Support Care Cancer - 2010 Manuscript - Primary - Primary - Symptom Inter - N03CA
A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance). Barton, Debra L , Atherton, Pamela J , Satele, Daniel V , Qin, Rui ... - - Support Care Cancer - 2020 Manuscript - Primary - Primary - Symptom Inter - NCCTG-N07C4
Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. Barton, Debra L , Wender, Donald B , Sloan, Jeff A , Dalton, Robert J ... - - J. Natl. Cancer Inst. - 2007 Manuscript - Primary - Primary - Symptom Inter - NCCTG-N02C3
Addressing the Complexities of Sexual Health in Female Cancer Survivors: NCCTG N10C1 (Alliance) Barton, Debra , Dockter, Travis , Atherton, Pamela , Lester, Joanne ... - CANS - - 2014 Abstract - Secondary - Primary - Symptom Inter - N10C1
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - JAMA Oncol - 2017 Manuscript - Secondary-not-in-original - Meta-Analysis - Health Outcome - CALGB-30607 , CALGB-30610 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-70501 , CALGB-70604 , CALGB-80405 , CALGB-90401
Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1 Brown, L. C. , Atherton, P. J. , Neben-Wittich, M. A. , Wender, D. B. ... - - Support Care Cancer - 2013 Manuscript - Secondary - Primary - Health Outcome - N09C1
Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392) Chauhan, C. , Atherton, P. J. , Satele, D. , Dueck, A. C. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary - Primary - Health Outcome - NCCTG-N0392
Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance) Dueck, A. C. , Singh, J. , Atherton, P. , Liu, H. , Novotny, P. ... - - Osteoporos Int - 2015 Manuscript - Secondary-not-in-original - Primary - Health Outcome - N02C1 , N03CC
Assessing the clinical significance of real-time Quality of Life (QOL) data in cancer patients treated with radiation therapy Halyard, M. Y. , Tan, A. D. , Callister, M. D. , Ashman, J. B. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary - Primary - Health Outcome - NCCTG-89-20-52
A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial. Jatoi, A , Steen, P D , Atherton, P J , Moore, D F , Rowland, K M ... - - Ann. Oncol. - 2017 Manuscript - Primary - Primary - Symptom Inter - N02C4
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8 Kearns, Ann E. , Northfelt, Donald W. , Dueck, Amylou C. ... - - Support Care Cancer - 2010 Manuscript - Primary - Primary - Symptom Inter - N01C8
NCCTG N08CA (Alliance): The use of Glutathione for Prevention of Paclitaxel/Carboplatin Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo-Controlled Study Leal, Alexis D. , Qin, Rui , Atherton, Pamela J. , Haluska, Paul ... - - Cancer - 2014 Manuscript - Primary - Primary - Symptom Inter - N08CA
Gabapentin for hot flashes in men: NCCTG trial N00CB Loprinzi, C. L. , Khoyratty, B. S. , Dueck, A. , Barton, D. L. ... - - J. Clin. Oncol. - 2007 Abstract - Primary - Primary - Symptom Inter - N00CB
Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An Alliance for Clinical Trials in Oncology study Loprinzi, C. L. , Qin, R. , Dakhil, S. R. , Fehrenbacher, L. ... - - J. Clin. Oncol. - 2013 Abstract - Primary - Primary - Symptom Inter - N08CB
Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance) Loprinzi, Charles L. , Qin, Rui , Dakhil, Shaker R. ... - - J. Clin. Oncol - 2014 Manuscript - Primary - Primary - Symptom Inter - N08CB
Phase III, Double-Blind Study of Depot Octreotide Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy: Results of North Central Cancer Treatment Group N00CA Martenson, James A. , Halyard, Michele Y. , Sloan, Jeff A. ... - - J Clin Oncol - 2008 Manuscript - Primary - Primary - Symptom Inter - N00CA
Mometasone Furoate Effect on Acute Skin Toxicity in Breast Cancer Patients Receiving Radiotherapy: A Phase 3 Double-Blind, Randomized Trial from the North Central Cancer Treatment Group N06C4 Miller, Robert C. , Schwartz, David J. , Sloan, Jeff A. ... - - Int J Radiat Oncol Biol Phys - 2011 Manuscript - Primary - Primary - Symptom Inter - N06C4
Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB Moraska, A. R. , Atherton, P. J. , Szydlo, D. W. , Barton, D. L. ... - - J Support Oncol - 2010 Manuscript - Primary - Primary - Symptom Inter - N00CB
Gabapentin for the management of hot flashes in prostate cancer survivors: A longitudinal continuation study—NCCTG trial N00CB Moraska, A. R. , Atherton, P. J. , Szydlo, D. W. , Barton, D. L. ... - - J. Clin. Oncol. - 2010 Abstract - Primary - Primary - Symptom Inter - N00CB
Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial Moraska, A. R. , Sood, A. , Dakhil, S. R. , Sloan, J. A. , Barton, D. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary - Primary - Symptom Inter - N05C7
Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4) Neben-Wittich, Michelle A. , Atherton, Pamela J. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2011 Manuscript - Secondary - Primary - Symptom Inter - N06C4
Electronic Patient-Reported Outcomes and Toxicities During Radiotherapy for Head and Neck Cancer Niska, Joshua R. , Halyard, Michele Y. , Tan, Angelina D. ... - - Qual Life Res - 2017 Manuscript - Secondary - Primary - Health Outcome - NCCTG-892052
NCCTG N10C2 (Alliance) – A Double-Blind, Placebo-Controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes Park, Haeseong , Qin, Rui , Smith, Thomas J. , Atherton, Pamela J. ... - - Menopause - 2015 Manuscript - Primary - Primary - Symptom Inter - N10C2
NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes Park, Haeseong , Qin, Rui , Smith, Thomas J. , Atherton, Pamela J. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - Symptom Inter - N10C2
Repeated Measures Analyses of Dermatitis Symptom Evolution in Breast Cancer Patients Receiving Radiotherapy in a Phase 3 Randomized Trial of Mometasone Furoate vs Placebo (N06C4 [Alliance]) Sio, Terence T. , Atherton, Pamela J. , Birckhead, Brandon J ... - - Support Care Cancer - 2016 Manuscript - Secondary - Primary - Symptom Inter - N06C4
Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial Sio, Terence T. , Atherton, Pamela J. , Pederson, Levi D. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2019 Manuscript - Primary - Primary - Symptom Inter - MC1221
A pilot, randomized trial of daily lisinopril vs placebo to prevent radiation-induced pulmonary distress (Alliance MC1221) Sio, Terence T. , Atherton, Pamela J. , Zhen, W. Ken ... - IASLC (WCLC) - - 2017 Abstract - Primary - Primary - Symptom Inter - NCT01880528
A novel approach of longitudinal adverse event evaluation in oncology clinical trials: the Toxicity over Time (ToxT) analysis of clinical trials N9741 and 979254 (Alliance) Thanarajasingam, Gita , Atherton, Pamela J. , Novotny, Paul J. ... - - Lancet Oncol. - 2016 Manuscript - Secondary-not-in-original - Primary - Health Outcome - N9741 , NCCTG-97-92-54
Beyond maximum grade: A novel, longitudinal toxicity over time (ToxT) adverse event analysis of lenalidomide in follicular lymphoma in Alliance A151617 Thanarajasingam, Gita , Dueck, Amylou , Novotny, Paul J. ... - ICML - Hematol Oncol - 2017 Abstract - Primary - Primary - Health Outcome - CALGB-50401 , A151617
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Thanarajasingam, Gita , Leonard, John P , Witzig, Thomas E ... - - Lancet Haematol - 2020 Manuscript - No-Endpoint - Other - Health Outcome - A151617 , CALGB-50401
Venlafaxine to prevent oxaliplatin-induced neuropathy?: A pilot randomized placebo-controlled trial. Zimmerman, Collin Thomas , Atherton, Pamela J. , Pachman, Deirdre R. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Primary - Symptom Inter - NCT01611155
Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy? A Pilot Randomized Placebo Controlled Trial Zimmerman, Collin , Atherton, Pam , Pachman, Deirdre , Seisler, Drew ... - MASCC / ISOO - Support Care Cancer - 2015 Abstract - Primary - Primary - Symptom Inter - NCT01611155
MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy Zimmerman, Collin , Atherton, Pamela J. , Pachman, Deirdre ... - - Support Care Cancer - 2016 Manuscript - Primary - Primary - Symptom Inter - NCT01611155
